Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: BMN 701 Switchover Study in Late-onset Pompe Disease
NCT01924845Phase 3Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2014
- Primary completion
- Sep 2016
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of reveglucosidase alfa in Pompe disease, sponsored by BioMarin Pharmaceutical. Started Apr 2014; status: terminated.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT01924845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01924845.